Support at Rs 315.20 below Rs 310.55. Resistance is at Rs 320.75 above Rs 324.50. (Sell for intraday with a stoploss above Rs 324.50)
[MACD SELL + VOLUME BUILD UP + BELOW 100 & 200 DMA]
BHEL (Rs 103.70)
Support at Rs 100 below Rs 97. Resistance is at Rs 105.50 above Rs 108. (Sell for intraday with a stoploss above Rs 108)
Also Read
SUN PHARMA (Rs 870.45)
Support at Rs 865.10 below Rs 862.25. Resistance is at Rs 883 above Rs 886.35. (Buy for intraday with a stoploss below Rs 862.25)
ASHAPURA MINECHEM (Rs 66.50)
Support at Rs 65.10 below Rs 64.25. Resistance is at Rs 67.90 above Rs 68.55. (Buy for intraday with a stoploss below Rs 64.25)
[VOLUME JUMP + ABV PREVIOUS CLOSE + MACD & STOCHASTICS BUY]
SURYA ROSHNI (Rs 136.30)
Support at Rs 133 below Rs 132.60. Resistance is at Rs 140.20 above Rs 142.55 (Buy for intraday with a stoploss below Rs 132.60)
[STOCHASTICS BUY+ VOLUME JUMP + ABV PREVIOUS CLOSE + ABV 200 DMA]
Disclaimer: This report has been prepared by Geojit BNP Paribas Financial Services Limited (GBNPP), here in after referred to as GBNPP. GBNPP, a publicly listed company, is engaged in services of retail broking, credit, portfolio management and marketing investment products including mutual funds, life and general insurance and properties. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved). This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. Opinion expressed herein is our current opinion as of the date appearing on this report only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app